Recent Updates
Recently added Catalysts

GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide

Phase 4

Hepatitis B | Vaccine | Infectious Disease |GSK plc|Trials Updated: Jan 15, 2026

GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide development status

Highest phase Phase 4 (NCT02901951)
Phase scored for GSKPhase 1
Registered trials 25 across 3 sponsors since Sep 2005

GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide target and mechanism

ModalityVaccine

Also known as Engerix-B

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials7
Total Enrollment1,706

FDA Designations

No designations recorded

GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide clinical trials

GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide · 7 trials · 1 indication

Phase 3 2Phase 2 4Phase 1 1
NCT00697840Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-BHepatitis B
COMPLETED150 Analytics
NCT00697242Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older AdultsHepatitis B
COMPLETED362 Analytics
PHASE3COMPLETED
Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B
Hepatitis BUnlock trial analytics
PHASE3COMPLETED
Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults
Hepatitis BUnlock trial analytics

Study Endpoints

Primary Endpoints

Anti-HBs antibody concentrations
At month 7
Occurrence and intensity of solicited local and general symptoms
4-day follow-up after vaccination
Occurrence of unsolicited adverse events
30-days after vaccination
Incidence of serious adverse events
Throughout the study period
Anti-hepatitis B surface antigen (HBs) antibody concentrations
At M2 and M7
Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells .
At Day 44

The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD40L), Interleukin (IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs). Results for the Day 44 time point are the primary results among the outcome measure results presented.

Number of Participants With Solicited Administration Site Adverse Events (AEs) After Dose 1
Day 1 (day of administration) to Day 14

Assessed solicited administration site events after vaccination included erythema, pain, and swelling at the injection site. Any = occurrence of the event regardless of intensity grade.

Number of Participants With Solicited Administration Site AEs After Dose 2
Day 31 (day of administration) to Day 45

Assessed solicited administration site events after vaccination included erythema, pain and swelling at the injection site. Any = occurrence of the event regardless of intensity grade.

Number of Participants With Solicited Systemic AEs After Dose 1
Day 1 (day of administration) to Day 14

Assessed solicited systemic events included fever (defined as temperature greater than or equal to (\>=) 38.0°C regardless of the location of measurement), fatigue, myalgia, arthralgia, headache, chills, malaise, loss of appetite, nausea, vomiting, and diarrhea.

Number of Participants With Solicited Systemic AEs After Dose 2
Day 31 (day of administration) to Day 45

Assessed solicited systemic events included fever (defined as temperature \>=38.0°C regardless of the location of measurement), fatigue, myalgia, arthralgia, headache, chills, malaise, loss of appetite, nausea, vomiting, and diarrhea.

Duration in Days of Solicited Administration Site AEs After Dose 1
Day 1 (day of administration) to Day 14

Duration is the number of days in which a participant experienced the symptom within the 14-day solicited follow-up period.

Duration in Days of Solicited Administration Site AEs After Dose 2
Day 31 (day of administration) to Day 45

Duration is the number of days in which a participant experienced the symptom within the 14-day solicited follow-up period.

Duration in Days of Solicited Systemic AEs After Dose 1
Day 1 (day of administration) to Day 14

Duration is the number of days in which a participant experienced the symptom within the 14-day solicited follow-up period.

Duration in Days of Solicited Systemic AEs After Dose 2
Day 31 (day of administration) to Day 45

Duration is the number of days in which a participant experienced the symptom within the 14-day solicited follow-up period.

Number of Participants With Any Unsolicited AEs After Dose 1
Day 1 (day of administration) to Day 31

An unsolicited AE is an AE that was not included in a list of solicited events using a Participant Diary. Unsolicited events must have been spontaneously communicated by a participant who has signed the informed consent. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.

Number of Participants With Any Unsolicited AEs After Dose 2
Day 31 (day of administration) to Day 61

Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.

Number of Participants With Serious AEs (SAEs)
Throughout the entire study period (from Day 1 to Day 361)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or is an abnormal pregnancy outcome. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination.

Number of Participants With Medically Attended AEs (MAEs)
Throughout the entire study period (from Day 1 to Day 361)

An MAE is any AE with medically attended visits that were not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any = occurrence of the MAE regardless of intensity grade or relation to the study vaccination.

Number of Participants With AEs Leading to Study Withdrawal
Throughout the entire study period (from Day 1 to Day 361)

An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact.

Number of Participants With Potential Mediated Immune Diseases (pIMDs)
Throughout the entire study period (from Day 1 to Day 361)

pIMDs are a subset of adverse events that include autoimmune diseases and other inflammatory and/or neurological disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination.

Mean Percent Change From Baseline (Pre-vaccination, Day 1) in Hematology and Biochemistry Parameters Post-dose 1
At Day 8 (relative to baseline [pre-vaccination Day 1])

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC).

Mean Percent Change From Baseline (Pre-vaccination, Day 1) in Hematology and Biochemistry Parameters Post-dose 2
At Day 38 (compared with baseline [pre-vaccination, Day 1])

In the analysis were included biochemistry parameters: ALT, AST, bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, WBC.

Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 1
At Day 1 (baseline)

In the analysis were included biochemistry parameters: ALT, AST, bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, WBC. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 8
At Day 8

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate transaminase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC).Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 31
At Day 31

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate transaminase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC).Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 38
At Day 38

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate transaminase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC).Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 61
At Day 61

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate transaminase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC).Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Secondary Endpoints

Anti-pre-S1 antibody concentrations
Screening, Months 1, 2, 3, 6, 7, 8 and 12, depending on group allocation
Anti-HBs antibody concentrations
Screening, Months 1, 2, 3, 6, 7, 8 and 12
Occurrence and intensity of local and general solicited symptoms
4-day after vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Group AEXPERIMENTAL -
Group BACTIVE_COMPARATOR -
Group CEXPERIMENTAL -
Group DACTIVE_COMPARATOR -
Group EEXPERIMENTAL -
GSK223192A 1 GroupEXPERIMENTALSubjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
GSK223192A 2 GroupEXPERIMENTALSubjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
GSK223192A 3 GroupEXPERIMENTALSubjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
Fendrix GroupEXPERIMENTALSubjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
Engerix-B GroupACTIVE_COMPARATORSubjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
Group FEXPERIMENTALSubjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
Group GEXPERIMENTALSubjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
Group HEXPERIMENTALSubjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
HBs-alum GroupACTIVE_COMPARATORParticipants received 3 doses of GSK's Hepatitis B (HBsAg) vaccine adjuvanted with aluminum hydroxide, at Day 1, Day 31 and Day 181.
HBs-AS03 GroupEXPERIMENTALParticipants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03, adjuvant system, at Day 1 and Day 31.
HBs-AS04 GroupEXPERIMENTALParticipants received 2 doses of GSK's HBsAg vaccine adjuvanted with GSK's AS04, adjuvant system, at Day 1 and Day 31.
HBs-AS37B GroupEXPERIMENTALParticipants received 2 doses of GSK's HBsAg (20 µg) candidate vaccine adjuvanted with GSK's AS37B adjuvant system (50 µg), at Day 1 and Day 31.
HBs-AS37A GroupEXPERIMENTALParticipants received 2 doses of GSK's HBsAg (20 µg) candidate vaccine adjuvanted with GSK's AS37A adjuvant system (100 µg), at Day 1 and Day 31.

Interventions

NameTypeDescription
Engerix™-BBIOLOGICALIntramuscular injection, 2 doses
HBV-MPL 208129BIOLOGICALIntramuscular injection, 2 doses
Vaccine containing HBsAg absorbed on aluminium salts - experimental formulationBIOLOGICALIntramuscular injection, 2 doses; experimental formulation
Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPLBIOLOGICALIntramuscular injection, 3 doses
Engerix-B™BIOLOGICAL2 doses intramuscular injections
Fendrix™BIOLOGICAL2 doses intramuscular injections
GSK Biologicals' Hepatitis B vaccines (GSK223192A)BIOLOGICAL2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
HBsAg (Booster injection)BIOLOGICALSingle dose intramuscular injection
HBV-MPL vaccine 208129BIOLOGICAL2-dose intramuscular injection
HBV-MPL vaccine (208129)BIOLOGICAL -
Hepatitis B vaccine, experimental formulationBIOLOGICALIntramuscular injection, 3 doses
HBV-MPL vaccineBIOLOGICALIntramuscular injection, 1 or 3 doses
GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxideCOMBINATION_PRODUCTThree doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide administered intramuscularly in the non-dominant arm, one each at Day 1, Day 31 and Day 181.
GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant systemBIOLOGICALTwo doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant systemBIOLOGICALTwo doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37B adjuvant system (50 μg)BIOLOGICALTwo doses of GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37B adjuvant system (50 μg) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37A adjuvant system (100 μg)BIOLOGICALTwo doses of GSK's HBsAg (20 μg )vaccine adjuvanted with GSK's AS37A adjuvant system (100 μg) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 40 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Between 18 and 40 years old. * Written informed consent will have been obtained from the subjects. * Good physical condition as established by physical examination and history taking at the time of entry. * Female participants will avoid becoming pregnant during the study peri...

Countries:AustriaBelgiumDenmarkIcelandGermanyUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide

What is GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide used for?

It is an investigational vaccine being developed for the prevention of Hepatitis B, an infectious disease of the liver. It combines Hepatitis B antigen with an aluminum hydroxide adjuvant and is intended to stimulate an immune response against the virus in adults.

Who is developing GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide?

The vaccine is being developed by GSK plc, the British pharmaceutical company that trades under the ticker GSK. GSK is the sponsor of the clinical program evaluating this adjuvanted Hepatitis B vaccine candidate.

What phase is GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide in?

It is in Phase 1 clinical development. The program has completed one Phase 1 trial, and no later-stage trials have been recorded. The vaccine remains investigational and has not been approved by the FDA.

What clinical trial has been conducted for GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide?

One Phase 1 trial has been completed: NCT05561673, titled A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years. It enrolled 122 participants across Belgium, Germany, and the United Kingdom.

How was the Phase 1 trial of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide designed?

NCT05561673 was a randomized, active-controlled Phase 1 study that enrolled 122 healthy adult volunteers aged 18 to 45 years. It was not double-blind. The trial assessed safety and immune response and has been completed.